|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Allogene Therapeutics, Inc. (ALLO) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
140,280,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Allogene Therapeutics is a clinical stage immuno-oncology company focused on the development of genetically engineered allogeneic T cell therapies for the treatment of cancer. Co.'s key product candidates, ALLO-501 and ALLO-501A, are engineered allogeneic Chimeric antigen receptor (CAR) T cell therapies that target CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. Co. is also developing engineered allogeneic CAR T cell product candidates for multiple myeloma, clear cell renal cell carcinoma, and other blood cancers and solid tumors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
190 |
190 |
190 |
| Total Buy Value |
$0 |
$683 |
$683 |
$683 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
1 |
1 |
1 |
| Total Shares Sold |
0 |
18,640 |
28,640 |
82,742 |
| Total Sell Value |
$0 |
$50,317 |
$93,172 |
$700,150 |
| Total People Sold |
0 |
1 |
2 |
5 |
| Total Sell Transactions |
0 |
1 |
2 |
12 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Chang David D |
President and CEO |
• • – |
2023-03-22 |
4 |
A |
$0.00 |
$0 |
D/D |
1,924,464 |
4,193,911 |
|
- |
|
| Schmidt Eric Thomas |
Chief Financial Officer |
• • – |
2023-03-22 |
4 |
A |
$0.00 |
$0 |
D/D |
558,094 |
862,439 |
|
- |
|
| Moore Alison |
Chief Technical Officer |
• • – |
2023-03-22 |
4 |
A |
$0.00 |
$0 |
D/D |
558,094 |
672,731 |
|
- |
|
| Chang David D |
President and CEO |
• • – |
2023-03-14 |
4 |
D |
$5.56 |
$124,210 |
D/D |
(22,340) |
2,269,447 |
|
- |
|
| Schmidt Eric Thomas |
Chief Financial Officer |
• – – |
2023-03-14 |
4 |
D |
$5.47 |
$196,258 |
D/D |
(35,879) |
304,345 |
|
- |
|
| Moore Alison |
Chief Technical Officer |
• • – |
2023-03-14 |
4 |
D |
$5.51 |
$45,990 |
D/D |
(8,351) |
114,637 |
|
- |
|
| Bhavnagri Veer |
General Counsel |
• • – |
2023-03-14 |
4 |
D |
$5.67 |
$133,971 |
D/D |
(23,628) |
556,049 |
|
- |
|
| Bhavnagri Veer |
General Counsel |
• • – |
2023-02-13 |
4 |
AS |
$6.85 |
$20,550 |
D/D |
(3,000) |
577,677 |
|
- |
|
| Roberts Zachary |
EVP of R&D |
• – – |
2023-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
251,908 |
251,908 |
|
- |
|
| Bhavnagri Veer |
General Counsel |
• • – |
2023-01-17 |
4 |
AS |
$7.04 |
$21,120 |
D/D |
(3,000) |
580,677 |
|
- |
|
| Bhavnagri Veer |
General Counsel |
• • – |
2022-12-15 |
4 |
AS |
$7.53 |
$42,186 |
D/D |
(5,602) |
583,677 |
|
- |
|
| Amado Rafael |
EVP of R&D |
• • – |
2022-10-07 |
4 |
D |
$11.83 |
$100,099 |
D/D |
(8,464) |
541,946 |
|
- |
|
| Amado Rafael |
EVP of R&D |
• • – |
2022-10-07 |
4 |
A |
$0.00 |
$0 |
D/D |
19,120 |
550,410 |
|
- |
|
| Amado Rafael |
EVP of R&D |
• • – |
2022-10-03 |
4 |
D |
$11.06 |
$99,201 |
D/D |
(8,968) |
531,290 |
|
- |
|
| Witte Owen N. |
Director |
– • – |
2022-08-12 |
4 |
S |
$17.25 |
$86,250 |
D/D |
(5,000) |
218,271 |
|
- |
|
| Witte Owen N. |
Director |
– • – |
2022-08-11 |
4 |
S |
$16.50 |
$165,000 |
D/D |
(10,000) |
223,271 |
|
- |
|
| Amado Rafael |
EVP of R&D and CMO |
• – – |
2022-08-02 |
4 |
AS |
$11.97 |
$23,940 |
D/D |
(2,000) |
540,257 |
|
- |
|
| Mayo Stephen |
Director |
– • – |
2022-07-08 |
4 |
A |
$0.00 |
$0 |
D/D |
35,328 |
35,328 |
|
- |
|
| Amado Rafael |
EVP of R&D and CMO |
• – – |
2022-07-05 |
4 |
AS |
$11.44 |
$22,880 |
D/D |
(2,000) |
542,257 |
|
- |
|
| Witte Owen N. |
|
– • – |
2022-06-22 |
4 |
S |
$11.76 |
$117,600 |
D/D |
(10,000) |
233,271 |
|
- |
|
| Amado Rafael |
EVP of R&D and CMO |
• – – |
2022-06-21 |
4 |
AS |
$11.18 |
$22,360 |
D/D |
(2,000) |
544,257 |
|
- |
|
| Kazam Joshoa A |
|
– • – |
2022-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
44,178 |
303,063 |
|
- |
|
| Sato Vicki L |
|
– • – |
2022-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
22,089 |
41,451 |
|
- |
|
| Witte Owen N. |
|
– • – |
2022-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
22,089 |
243,271 |
|
- |
|
| Humer Franz B |
|
– • – |
2022-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
44,178 |
191,892 |
|
- |
|
221 Records found
|
|
Page 2 of 9 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
